Toggle navigation
Home
Search
Services
Blog
Contact
About
Novel CB1 Receptor Antagonist: Phase II-271077424
Makscientific. LLC
Search grants from Makscientific. LLC
Share this grant:
:
:
Abstract
Funding
Institution
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Large-Scale Methylation Profiling in Metabolic Syndrome Phenotypes
Improving Research Capacity in Cameroon for Studies on HIV-Associated Malignancie
Morphomic Analysis of a Simple Chordate
Novel microbicides to prevent and treat HSV
Mechanisms of Ion Channel Activity
Recently added grants:
Regulation of Germ Cell Fate During Embryogenesis
RFA-DD-18-001 Birth Defects Study To Evaluate Pregnancy exposures (BD-STEPS) II Core & Component B Steps -Stillbirth
Feasibility of Mobile Technology-Based Assessments of Community Reintegration in Homeless Veterans
Workplace Violence in Outpatient Physician Clinics
Hybridized structure- and ligand- based drug discovery approaches targeting ASCT2, an amino acid transporter critical for upregulated cell proliferation in numerous cancer types
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Business Innovation Research – Phase II (N44)
Project #
N44DA077424-001
Application #
7329591
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2006
Total Cost
Indirect Cost
Institution
Name
Makscientific. LLC
Department
Type
DUNS #
City
State
Country
Zip Code
Comments
Be the first to comment on this grant